Literature DB >> 12833247

Calcitonin in the treatment of transient osteoporosis of the hip.

Thurayya K Arayssi1, Hussein A Tawbi, Ihab M Usta, Mukbil H Hourani.   

Abstract

BACKGROUND: Transient osteoporosis of the hip (TOH) is a rare clinical disorder of unknown etiology characterized by hip pain and functional disability that resolve spontaneously in 6-24 months.
OBJECTIVES: To report 2 patients with TOH during pregnancy who had rapid resolution of their illness with the use of calcitonin. To review the literature on TOH with special emphasis on its treatment.
METHODS: A MEDLINE search of studies published from 1966 to 2002 was performed to review treatment options for TOH and their effect on the natural history of the disease.
RESULTS: Our 2 patients developed hip pain during pregnancy with classical changes of TOH on MRI. Both patients received calcitonin, 1 during pregnancy and 1 postpartum with resolution of their symptoms within 6 to 9 weeks. Previous reports in the literature of treatment of TOH showed that antiresorptive agents (bisphosphonates and calcitonin) had shortened the duration of the illness compared with the natural history of the disease.
CONCLUSIONS: TOH is an under-recognized entity associated with pain and disability. The use of antiresorptive agents may be of help in reducing the duration of the disease. RELEVANCE: To increase the recognition of TOH and to consider therapeutic interventions to shorten the duration of the disease. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833247     DOI: 10.1053/sarh.2002.50014

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  11 in total

Review 1.  Transient osteoporosis of the hip: review of the literature.

Authors:  K Asadipooya; L Graves; L W Greene
Journal:  Osteoporos Int       Date:  2017-03-17       Impact factor: 4.507

2.  Transient osteoporosis associated with pregnancy: use of bisphosphonate in treating a lactating mother.

Authors:  N G Shenker; M F Shaikh; A S M Jawad
Journal:  BMJ Case Rep       Date:  2010-12-14

3.  [Therapy of bone marrow edema syndrome in the knee with denosumab. Case report].

Authors:  T Geith; W Mutschler; F Berger
Journal:  Unfallchirurg       Date:  2015-03       Impact factor: 1.000

4.  Transient osteoporosis of the hip/bone marrow edema syndrome with soft tissue involvement: a case report.

Authors:  Aref A Bin Abdulhak; Fawziah A Ba-Mougadam; Nizar A Al-Nakshabandi; Mohamad A Al-Tannir
Journal:  Oman Med J       Date:  2011-09

5.  Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.

Authors:  J D Ringe; A Dorst; H Faber
Journal:  Osteoporos Int       Date:  2005-10-14       Impact factor: 4.507

6.  Oral bisphosphonates in treatment of transient osteoporosis.

Authors:  L Kibbi; Z Touma; N Khoury; T Arayssi
Journal:  Clin Rheumatol       Date:  2007-10-16       Impact factor: 2.980

7.  [Transient osteoporosis of the hip in pregnancy. Successful treatment with calcitonin: a case report].

Authors:  N Laktasic-Zerjavic; B Curkovic; D Babic-Naglic; K Potocki; M Prutki; D Soldo-Juresa
Journal:  Z Rheumatol       Date:  2007-10       Impact factor: 1.372

8.  Clinical effect of intramuscular calcitonin compared with oral celecoxib in the treatment of knee bone marrow lesions: a retrospective study.

Authors:  Jiaming Zhou; Wuyi Xiong; Pengguo Gou; Zhao Chen; Xing Guo; Xiaoyang Huo; Yuan Xue
Journal:  J Orthop Surg Res       Date:  2020-06-23       Impact factor: 2.359

9.  Idiopathic Transient Osteoporosis during Pregnancy - Report of a Clinical Case.

Authors:  Frederico Paiva; Nuno Simões; David Pereira; Nuno Borralho
Journal:  J Orthop Case Rep       Date:  2020

10.  Clinical efficacy of calcitonin compared to diclofenac sodium in chronic nonspecific low back pain with type I Modic changes: a retrospective study.

Authors:  Jiaming Zhou; Tengshuai Li; Liandong Li; Yuan Xue
Journal:  J Pain Res       Date:  2018-07-17       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.